Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
On Monday, Qiagen NV (NYSE:QGEN) announced at its Capital Markets Day a comprehensive strategy aimed at delivering solid and profitable growth through 2028.
The company targets a 7% compound annual sales growth at constant exchange rates (CER) by 2028.
At the event, the German molecular diagnostics firm announced its plans to return at least $1 billion to shareholders from 2024 to 2028, barring value-creating M&A opportunities while maintaining high levels of organic business investments.
Key strategic pillars for growth include:
“Given our healthy balance sheet and cash flow generation, we are announcing a commitment for significant returns to shareholders while maintaining a high level of investments into our business and seeking value-creating M&A opportunities that strengthen our portfolio and create greater value,” the company added
QIAGEN aims to achieve a 31% CER-adjusted operating income margin by 2028 through portfolio streamlining, organizational simplification, and digitization.
These efforts include discontinuing the NeuMoDx system and upgrading the SAP enterprise resource system.
QIAGEN returned $300 million to shareholders via a synthetic share repurchase in January 2024 and plans a new $300 million program pending shareholder approval at the Annual General Meeting.
Price Action: QGEN shares are up 2.79% at $43.52 at last check Monday.
Now Read: GameStop Shareholders Meeting Highlights: ‘Actions Speak Louder Than Words,’ Says CEO Ryan Cohen
Image created using artificial intelligence via Midjourney.
Posted In: QGEN